A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function
Purpose: Study with Combination Therapy Ivacaftor and VX-661 for subjects older than 12 years of age with Cystic Fibrosis genotype heterozygote.
Sponsor: Vertex Pharmaceuticals
Principal Investigator: Cori Daines, MD
Osmara Y. Molina de Rodriguez, MS
Cell: (520) 891-6767 or Office: (520) 626-3910